Slide 1: A New Paradigm in Oral Drug Delivery with the Precision Timed Release Platform
A New Paradigm in Oral Drug Delivery with the Precision Timed Release™ Platform Cingulate | Corporate Presentation 2Q 2026
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than st
Slide 3: Why Cingulate (Nasdaq: CING)
3 Why Cingulate (Nasdaq: CING) Near-Term Catalysts = Market Opportunity o CTx-1301 Commercial Launch planned 1H 2027 o 100 million prescriptions in $10Bn target market o Clear Differentiation with Unprecedented Clinical Data o Leadership Team with 90+ years of ADHD Experience Long-Term Catalysts = V
Slide 4: Cingulate Leadership Team
4 CINGULATE LEADERSHIP TEAM • Pharmaceutical Executive Leader: 30+ years in CEO, • Experienced Financial Leader: 30+ years in Board of Director, and diverse roles across biotech & accounting and financial management across a variety pharma. Doctor of Pharmacy. Cingulate Co-Founder. of industries. •
Slide 5: The Near-Term Opportunity
The Near-Term Opportunity CTx-1301 in US ADHD Market Ø Over 100 Million Prescriptions Ø Significant Unmet Needs and Dissatisfaction with Current Treatments CING-US-130-0426
Slide 6: The Market Opportunity
6 The Market Opportunity >100 Million Prescriptions ADHD STIMULANTS ~90% Extended-Release Stimulants or Boosters 1% Stimulant Market Share = Assume 25% $ 250-300M Dissatisfaction ~20M Rx Opportunity 10% Targeted Market Share = $495/Rx $1Bn Avg Brand $/Rx* $10 Bn MARKET * Not indicating CTx-1301 Pric
Slide 7: The Problem: Where Today's ADHD Therapies May Fall Short
7 The Problem: Where Today’s ADHD Therapies May Fall Short What Does Differentiation Look Like? ADHD BRANDS APPROVED ATTRIBUTES1 UNMET NEEDS1 Fast Onset of Duration Action Entire Active- Minimize Onset (hr) (less onset) ≤ 30 min Day Efficacy* Crash/Rebound Avoid Booster1 92% Vyvanse® 2007 1½-2 8-9 h
Slide 8: Recent Launches Lack Meaningful Clinical Innovation
8 Recent Launches Lack Meaningful Clinical Innovation ADHD BRANDS ATTRIBUTES1 UNMET NEEDS Fast Acting Entire Active- Avoid Avoid Product Onset Duration (≤ 30 min) Day Efficacy* Crash/Rebound Booster Quillivant / Chew® XR 60 mins 8 hours û û û û Mydayis® 2 or 4 hrs 16+ hours û û û û Adzenys® ER/ODT 6
Slide 9: Precision Timed Release (PTR) Platform Unlocks True Once-daily, Multi-dose Tablets
9 Focus had to be on groundbreaking delivery technology Precision Timed Release™ (PTR™) Platform Unlocks the Possibility for ‘True’ Once-daily, Multi-dose Tablets Immediate Release Third Erosion Release Barrier Layers Second Release Film Coat See the PTR™ Platform in Action @ Cingulate.com *Symphony
Slide 10: The Solution
The Solution Clinical Evidence CING-US-130-0426
Slide 11: One Product Designed to Overcome All Unmet Needs
11 One Product Designed to Overcome All Unmet Needs Entire Active-Day Efficacy, Stop the Crash & Rebound, Eliminate Booster Doses 3pm 7am Noon Built In Booster Subject ID: 01-510 CTx-1301 6.25-mg 2 Focalin XR 5-mg 1 3 Fast Onset Extended Efficacy Cingulate.com © 2026 Cingulate Inc. CING-US-130-0426
Slide 12: Percent Improvement PERMP – Adult Laboratory Classroom
12 PERMP – Adult Laboratory Classroom 40 CTx-1301 (N=11) Placebo (N=10) ** 111% 35 * p < 0.05 ** p = 0.10 - 0.05 65% ** p = 0.089 Overall Standard of Care 30 * 57% 49% 141% * Percent Improvement 25 213% 91% Over Placebo 52% Active-Day ** 88% Improvement 20 158% vs Placebo 15 100% 10 5 0 30 MINUTES 1
Slide 13: CTx-1301 PERMP Effect Size over Entire Active Day
13 CTx-1301 PERMP Effect Size over Entire Active Day A Meta-Analysis conducted by Faraone and Glatt (Clin Psych 71:6 3.00 June 2010)1 using 11 published studies with long-acting stimulants in adults demonstrated the Average Stimulant Effect Size to be 0.73 60 (approximate range 0.5 to 0.9).1 2. 2.50
Slide 14: CTx-1301 Demonstrated Significantly Lower Adverse Events
14 CTx-1301 Demonstrated Significantly Lower Adverse Events 28.6% reduction in TEAE’s related to CTx-1301 versus Focalin XR (14.3% difference) Focalin XR CTx-1301 Focalin XR CTx-1301 All All 5 mg 6.25 mg 40 mg 50 mg CTx-1301 Focalin XR (n=41) (n=39) (n=43) (n=42) (n=42) (n=44) Patients with at least
Slide 15: The ADHD Medication Providing Daily Durability
The ADHD Medication Providing Daily Durability Precision Timed ReleaseTM (PTRTM) Platform Unlocks the Possibility for ‘True’ Once-daily, Multi-dose Tablets $10 Bn Opportunity Fast Onset Reduce or Eliminate Need for Dominated of Action ‘Booster/Recovery’ Meds by Stimulants Over 100 Reduce or Eliminat
Slide 16: How Cingulate Achieves It
How Cingulate Achieves It Commercialization & Go-To-Market Strategy CING-US-130-0426
Slide 17: Cingulate Driven Commercialization Leveraging Best in Industry Partners
Cingulate Driven Commercialization Leveraging Best in Industry Partners Cingulate.com © 2026 Cingulate Inc. CING-US-130-0426
Slide 18: Launch Ready with Best in Industry Commercialization
Launch Ready with Best in Industry Commercialization Essential Factors To Drive Demand 1. Reimbursement Cingulate Sales Professional Team: • Payer Research indicates Positive Acceptance for Reimbursement • 110 – 120 FTEs at Launch • Pricing & Contracting to Maximize GTN and ‘Lives Covered’ • 25-40 S
Slide 19: Pressure Testing Cingulate's G2M Strategy
19 Pressure Testing Cingulate’s G2M Strategy ~500,000 US ADHD Providers ADHD Providers by Specialty (vol) Ø Psychiatry: 50% 80% of ADHD TRx’s written by Ø Pediatrician: 30% 100,000 Providers 60% TRx’s = 50,000 Providers Psychiatry: Ø Largely tele/video 54,000 ADHD Providers medicine today Reached on
Slide 20: Go To Market Execution – Implementing the Entire Big Pharma Toolbox
Go To Market Execution – Implementing the Entire Big Pharma Toolbox 12-months to 9-months to 2-4-months to Launch & Launch Launch Launch BEYOND Phase 1: Market Conditioning Phase 2: Market Access Phase 3: Precision Targeting, Phase 4: Post-Launch & Medical Affairs & Payor Strategy Messaging, Optimiz
Slide 21: Research Shows Favorable Reimbursement Potential
21 Research Shows Favorable Reimbursement Potential Executive Summary of Qualitative Findings (July 2, 2024): ~122M covered lives Ø CTx-1301 was rated most valuable versus Vyvanse, Adderall XR, Concerta, Focalin XR, Azstarys, and Qelbree. Ø CTx-1301 is likely to gain Commercial and Medicaid coverage
Slide 22: Path to Market
Path to Market Milestones Capital CING-US-130-0426
Slide 23: Path to Market
23 Path to Market Near-term Milestones Driving 12-Month Value NDA Filing NDA Acceptance PDUFA Date Set as Anticipated Approval Commercial Launch July 31, 2025 October 14, 2025 May 31, 2026 2H26 1H27 Funding Outlook: • 9+ months cash on hand • Mix of Royalty – Debt – Equity Capital Cingulate.com © 20
Slide 24: The Future
The Future Vast Pipeline Opportunities via PTR™ Platform CING-US-130-0426
Slide 25: PTR Facilitates a Potential Pipeline Addressing Multiple Indications
25 PTR Facilitates a Potential Pipeline Addressing Multiple Indications Identified Targets for PTRTM Platform Pipeline Significant Unmet Needs in Billion Dollar Markets In Development Near-Term Targets Identified Future Therapeutic Areas • ADHD (CTx-1301, 1302) • Insomnia • Migraine • Anxiety (CTx-2
Slide 26: Thank You
CINGULATE’ Thank You < AGO ase ; es